Laserfiche WebLink
APPENDIX <br />Repealed Minnesota Statutes: HO100-9 <br />Subd. 1 c. Notice to patients. Upon the revocation or nonrenewal of a manufacturer's registration <br />under subdivision 1 a or implementation of an enforcement action under subdivision 1 b that may <br />affect the ability of a registered patient, registered designated caregiver, or a registered patient's <br />parent, legal guardian, or spouse to obtain medical cannabis from the manufacturer subject to the <br />enforcement action, the commissioner shall notify in writing each registered patient and the patient's <br />registered designated caregiver or registered patient's parent, legal guardian, or spouse about the <br />outcome of the proceeding and information regarding alternative registered manufacturers. This <br />notice must be provided two or more business days prior to the effective date of the revocation, <br />nonrenewal, or other enforcement action. <br />Subd. 2. Range of compounds and dosages; report. The commissioner shall review and <br />publicly report the existing medical and scientific literature regarding the range of recommended <br />dosages for each qualifying condition and the range of chemical compositions of any plant of the <br />genus cannabis that will likely be medically beneficial for each of the qualifying medical conditions. <br />The commissioner shall make this information available to patients with qualifying medical <br />conditions beginning December 1, 2014, and update the information annually. The commissioner <br />may consult with the independent laboratory under contract with the manufacturer or other experts <br />in reporting the range of recommended dosages for each qualifying medical condition, the range <br />of chemical compositions that will likely be medically beneficial, and any risks of noncannabis <br />drug interactions. The commissioner shall consult with each manufacturer on an annual basis on <br />medical cannabis offered by the manufacturer. The list of medical cannabis offered by a manufacturer <br />shall be published on the Department of Health website. <br />Subd. 3. Deadlines. The commissioner shall adopt rules necessary for the manufacturer to begin <br />distribution of medical cannabis to patients under the registry program by July 1, 2015, and have <br />notice of proposed rules published in the State Register prior to January 1, 2015. <br />Subd. 4. Reports. (a) The commissioner shall provide regular updates to the task force on <br />medical cannabis therapeutic research and to the chairs and ranking minority members of the <br />legislative committees with jurisdiction over health and human services, public safety, judiciary, <br />and civil law regarding: (1) any changes in federal law or regulatory restrictions regarding the use <br />of medical cannabis or hemp; and (2) the market demand and supply in this state for products made <br />from hemp that can be used for medicinal purposes. <br />(b) The commissioner may submit medical research based on the data collected under sections <br />152.22 to 152.37 to any federal agency with regulatory or enforcement authority over medical <br />cannabis to demonstrate the effectiveness of medical cannabis for treating a qualifying medical <br />condition. <br />152.26 RULEMAKING. <br />(a) The commissioner may adopt rules to implement sections 152.22 to 152.37. Rules for which <br />notice is published in the State Register before January 1, 2015, may be adopted using the process <br />in section 14.389. <br />(b) The commissioner may adopt or amend rules, using the procedure in section 14.386, <br />paragraph (a), to implement the addition of dried raw cannabis as an allowable form of medical <br />cannabis under section 152.22, subdivision 6, paragraph (a), clause (4). Section 14.386, paragraph <br />(b), does not apply to these rules. <br />152.261 RULES; ADVERSE INCIDENTS. <br />(a) The commissioner of health shall adopt rules to establish requirements for reporting incidents <br />when individuals who are not authorized to possess medical cannabis under sections 152.22 to <br />152.37 are found in possession of medical cannabis. The rules must identify professionals required <br />to report, the information they are required to report, and actions the reporter must take to secure <br />the medical cannabis. <br />(b) The commissioner of health shall adopt rules to establish requirements for law enforcement <br />officials and health care professionals to report incidents involving an overdose of medical cannabis <br />to the commissioner of health. <br />(c) Rules must include the method by which the commissioner will collect and tabulate reports <br />of unauthorized possession and overdose. <br />152.27 PATIENT REGISTRY PROGRAM ESTABLISHED. <br />Subdivision 1. Patient registry program; establishment. (a) The commissioner shall establish <br />a patient registry program to evaluate data on patient demographics, effective treatment options, <br />9R <br />